In the orthotopic RENCAluc kidney cancer model—where in vivo PD-L1 expression was almost negligible within the primary tumour and sparse within lung metastases—sunitinib plus anti-PD-L1 was an effective combination in the adjuvant therapy setting but not in the primary tumour or advanced metastatic disease settings. The gene discussed is CD274; the disease is metastatic neoplasm.